CVS Health Q3 2025 Earnings Call

These sources present the unaudited condensed consolidated financial statements and management's discussion and analysis for CVS Health Corporation for the nine months ended September 30, 2025. The documents detail the company’s financial performance, including a significant net loss attributable to CVS Health of over $3.9 billion for the three months ended September 30, 2025, largely due to a $5.7 billion goodwill impairment charge related to the Health Care Delivery reporting unit and substantial legacy and opioid litigation charges. They also outline the company's four reportable segments—Health Care Benefits, Health Services, Pharmacy & Consumer Wellness, and Corporate/Other—and provide forward-looking statements alongside updated 2025 full-year guidance, which includes a lowered GAAP diluted earnings per share range but a raised Adjusted EPS range. Furthermore, the text addresses recent accounting pronouncements and operational highlights, such as Aetna's strong Medicare Advantage Star Ratings, even as the company faces high utilization rates and regulatory pressures.